Fluorine 18 MK 6240

Drug Profile

Fluorine 18 MK 6240

Alternative Names: [18F]MK 6240; [18F]MNI-946; Fluorine-18-MK6240; MK-6240

Latest Information Update: 03 Jul 2017

Price : $50

At a glance

  • Originator Merck Sharp & Dohme
  • Developer Merck Sharp & Dohme; Molecular NeuroImaging
  • Class Imaging agents; Radiopharmaceuticals
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 26 Jun 2017 Cerveau Technologies signs a research agreement with NYU Langone Medical Center for Alzheimer's disease
  • 16 Jun 2017 US FDA approves IND application for Flourine 18 MK 6240 in Alzheimer's disease (Diagnosis)
  • 16 Jun 2017 Cerveau Technologies and Merck plan a clinical trial for Alzheimer's disease (Diagnosis) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top